The renal cell carcinoma (RCC) is the eight most common and aggressive cancer. Unfortunately, there are poor treatments methods. Right now, the only curative treatment for localized RCC is surgery. The management of the primary tumor has changed due to the realization that clean margins around the primary lesion, are sufficient to prevent local recurrence, as well as the development of more specific tools that increase the safety of partial nephrectomy. Improved diagnostic methods facilitating early detection and characterization of renal tumors have enabled effective use of less invasive treatments.
Unfortunately, when is diagnosed in advanced stages, there is no much to do, due to the lack of more specific treatments. A few standard treatments for advanced RCC are largely unsuccessful and radiotherapy is used for symptoms associated with RCC in patients not eligible for surgery. Moreover, there is immunotherapy with cytokines, which is the standard systemic treatment for RCC, but it is not well tolerated.
There are other studies evaluating different approaches. Most of them saw that the main problem is the well-known tolerability by the immune system to the cancer cells. Therefore, they are evaluating how the activation of T-cells can occur without triggering other complex signals that can give as a result some serious adverse events on patients, for example, autoimmune phenotypes.
Actually, we are about to start a protocol that propose a novel treatment for renal cell carcinoma and the main objective is to see not only the efficacy, but also how well is tolerated for the patients. Therefore, it’s important to be careful about how the drug is administered, follow-up of patients, and everything that involves the patient participation, so the data can be accurate. We have plenty of experience working with these complex protocols and we are happy to be part of novel research approaches.